Advertisement

Cancer Chemotherapy and Pharmacology

, Volume 56, Issue 5, pp 473–480 | Cite as

Augmenting tumor sensitivity to topotecan by transient hypoxia

  • Eva L. LundEmail author
  • Lasse T. Hansen
  • Paul E. G. Kristjansen
Original Article

Abstract

We examined how the effect of topotecan is modulated by transient hypoxia in three different tumor lines, Lewis lung carcinoma (LLC), U87 human glioblastoma and DMS273 human small cell lung cancer. Four groups of tumor bearing mice were treated with saline or a single dose of topotecan, immediately followed by 6-h or 72-h exposure to a hypoxic environment (10% O2) or normal air. Topotecan + hypoxia resulted in significantly greater suppression of tumor growth than normoxic topotecan or hypoxia alone. Correspondingly, the sensitivity of LLC cells to topotecan in a clonogenic survival assay was significantly higher under hypoxia. This effect of hypoxia was not a general phenomenon, since the tumor growth inhibitory effect of the alkylating agent cisplatin was not changed by hypoxic environment. In a parallel series of in vitro experiments, cell cultures were exposed to hypoxia (0.1% or 0.7% O2) in a hypoxic chamber or normoxia for 24 h. We found a dose-dependent downregulation of HIF-1α by topotecan (30–270 nM). The hypoxic upregulation of Glucose transporter-1 and VEGF secretion to the culture medium was inhibited by the addition of topotecan, while doses up to 270 nM had no effect on VEGF under normoxia. VEGF protein levels in tumors were also reduced by topotecan. These data show that the effect of topotecan is increased by transient hypoxia, and this may be a direct effect on the ability of cells to survive under hypoxia as well as an antiangiogenic effect, mediated through the HIF-1 inhibitory effect of topotecan.

Keywords

Topotecan Vascular Endothelial Growth Factor Hypoxia Hypoxia inducible factor 1 Lung cancer 

Notes

Acknowledgements

The authors would like to thank Jette Christiansen and Pia G. Knudsen for their expert technical assistance. This research was supported by grants from the Danish Cancer Society, Danish Cancer Research Foundation and the Danish Medical Research Council.

References

  1. 1.
    Rapisarda A, Uranchimeg B, Scudiero DA., Selby M, Sausville EA, Shoemaker RH, Melillo G (2002) Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. Cancer Res 62:4316-4324PubMedGoogle Scholar
  2. 2.
    Rapisarda A, Uranchimeg B, Sordet O, Pommier Y, Shoemaker RH, Melillo G (2004) Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications. Cancer Res 64:1475-1482PubMedGoogle Scholar
  3. 3.
    Hsiang YH, Liu LF (1988) Identification of mammalian dna topoisomerase-I as an intracellular target of the anticancer drug camptothecin. Cancer Res 48:1722-1726PubMedGoogle Scholar
  4. 4.
    Redinbo MR, Stewart L, Kuhn P, Champoux JJ, Hol WGJ (1998) Crystal structures of human topoisomerase I in covalent and noncovalent complexes with DNA. Science 279:1504-1513CrossRefPubMedGoogle Scholar
  5. 5.
    Schneider E, Hsiang YH, Liu LF (1990) DNA topoisomerases as anticancer drug targets. Adv Pharmacol 21:149-183PubMedGoogle Scholar
  6. 6.
    Pizzolato JF, Saltz LB (2003) The camptothecins. Lancet 361:2235-2242CrossRefPubMedGoogle Scholar
  7. 7.
    Nagourney RA, Sommers BL, Harper SM, Radecki S, Evans SS (2003) Ex vivo analysis of topotecan: advancing the application of laboratory-based clinical therapeutics. Br J Cancer 89:1789-1795CrossRefPubMedGoogle Scholar
  8. 8.
    Lima CMR, Chiappori A (2003) Treatment of relapsed small-cell lung cancer—a focus on the evolving role of topotecan. Lung Cancer 40:229-236CrossRefPubMedGoogle Scholar
  9. 9.
    Semenza GL (1998) Hypoxia-inducible factor 1: master regulator of O2 homeostasis. Curr Opin Genet Dev 8:588-594CrossRefPubMedGoogle Scholar
  10. 10.
    Harris AL (2002) Hypoxia–a key regulatory factor in tumour growth. Nat Rev Cancer 2:38-47CrossRefPubMedGoogle Scholar
  11. 11.
    Bruick RK, McKnight SL (2001) A conserved family of prolyl-4-hydroxylases that modify HIF. Science 294:1337-1340CrossRefPubMedGoogle Scholar
  12. 12.
    Epstein ACR, Gleadle JM, McNeill LA, Hewitson KS, O’Rourke J, Mole DR, Mukherji M, Metzen E, Wilson MI, Dhanda A., Tian YM, Masson N, Hamilton DL, Jaakkola P, Barstead R, Hodgkin J, Maxwell PH, Pugh CW, Schofield CJ, Ratcliffe PJ (2001) C-elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107:43–54CrossRefPubMedGoogle Scholar
  13. 13.
    Semenza GL (2003) Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3:721–732CrossRefPubMedGoogle Scholar
  14. 14.
    Giaccia A, Siim BG, Johnson RS (2003) HIF-1 as a target for drug development. Nat Rev Drug Dis 2:803–811CrossRefGoogle Scholar
  15. 15.
    Rygaard K, Spang-Thomsen M (1997) Quantitation and gompertzian analysis of tumor growth. Breast Cancer Res Treat 46:303-312CrossRefPubMedGoogle Scholar
  16. 16.
    Flowers JL, Hoffman RM, Driscoll TA, Wall ME, Wani MC, Manikumar G, Friedman HS, Dewhirst M, Colvin OM, Adams DJ (2003) The activity of camptothecin analogues is enhanced in histocultures of human tumors and human tumor xenografts by modulation of extracellular pH. Cancer Chemother Pharmacol 52:253–261CrossRefPubMedGoogle Scholar
  17. 17.
    Lund EL, Hog A, Olsen MW, Hansen LT, Engelholm SA., Kristjansen PE (2004) Differential regulation of VEGF, HIF1alpha and angiopoietin-1, −2 and −4 by hypoxia and ionizing radiation in human glioblastoma. Int J Cancer 108:833–838CrossRefPubMedGoogle Scholar
  18. 18.
    Bentzen L, Keiding S, Horsman MR, Gronroos T, Hansen SB, Overgaard J (2002) Assessment of hypoxia in experimental mice tumours by [18F]fluoromisonidazole PET and pO2 electrode measurements. Influence of tumour volume and carbogen breathing. Acta Oncol 41:304–312CrossRefPubMedGoogle Scholar
  19. 19.
    Becker A., Kuhnt T, Liedtke H, Krivokuca A., Bloching M, Dunst J (2002) Oxygenation measurements in head and neck cancers during hyperbaric oxygenation. Strahlenther Onkol 178:105–108CrossRefPubMedGoogle Scholar
  20. 20.
    Alavi A, Hood JD, Frausto R, Stupack DG, Cheresh DA (2003) Role of Raf in vascular protection from distinct apoptotic stimuli. Science 301:94–96CrossRefPubMedGoogle Scholar
  21. 21.
    Clements MK, Jones CB, Cumming M, Daoud SS (1999) Antiangiogenic potential of camptothecin and topotecan. Cancer Chemother Pharmacol 44:411–416CrossRefPubMedGoogle Scholar
  22. 22.
    O’Leary JJ, Shapiro RL, Ren CJ, Chuang N, Cohen HW, Potmesil M (1999) Antiangiogenic effects of camptothecin analogues 9-amino-20(S)camptothecin, topotecan, and CPT-11 studied in the mouse cornea model. Clin Cancer Res 5:181–187PubMedGoogle Scholar
  23. 23.
    Asahara T, Bauters C, Zheng LP, Takeshita S, Bunting S, Ferrara N, Symes JF, Isner JM (1995) Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo. Circulation 92:II365–371PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2005

Authors and Affiliations

  • Eva L. Lund
    • 1
    • 2
    Email author
  • Lasse T. Hansen
    • 1
  • Paul E. G. Kristjansen
    • 1
  1. 1.Laboratory of Experimental Oncology, Department of Molecular PathologyUniversity of CopenhagenCopenhagenDenmark
  2. 2.Molecular PathologyUniversity of CopenhagenCopenhagenDenmark

Personalised recommendations